Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewZD 9379 is a NMDA receptor antagonist; acts at glycine site. Neuroprotective; reduces infarct size and frequency of spreading depressions in a rat model of ischemic stroke. Brain penetrant.
Sold for research purposes under agreement from AstraZeneca
分子量 | 383.79 |
公式 | C19H14ClN3O4 |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 170142-20-8 |
PubChem ID | 9843028 |
InChI Key | PSTDMIAVUUYOOQ-UHFFFAOYSA-N |
Smiles | O=C2C3=C(C(NN(C4=C(C)C=C(OC)C=C4)C3=O)=O)NC1=CC(Cl)=CC=C12 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Bare (1993) Pyridazino[4,5-b]quinolinediones: a series of novel glycine site NMDA antagonists with potent in vitro and in vivo properties. Abstracts of Papers of the ACS 205 79. Abstract.
Takano (1997) Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke. 28 1255 PMID: 9183359
Tatlisumak (2000) A glycine antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Acta.Neurochir.Suppl. 76 331 PMID: 11450037
关键词: ZD 9379, ZD 9379 supplier, ZD9379, glycine, antagonists, NMDA, neuroprotectives, brain, penetrant, Receptors, 3322, Tocris Bioscience
目前没有该产品的评论。 Be the first to review ZD 9379 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.